Fraunhofer USA Center for Molecular Biotechnology to Use iBioPharma, Inc.'s Technology for Pandemic Flu Vaccine Research

NEWARK, Del.--(BUSINESS WIRE)--iBioPharma, Inc. (OTCBB:IBPM) partner Fraunhofer USA Center for Molecular Biotechnology (CMB) announced today that it has received an $8.7 million grant from the Bill & Melinda Gates Foundation for clinical development of an avian influenza vaccine based upon iBioPharma’s proprietary technology. The new funding will support CMB’s continued work to develop vaccines against avian influenza and advance promising candidates into clinical trials. A not-for-profit research organization, CMB uses iBioPharma’s proprietary transient plant-based technology to develop and manufacture novel vaccines and therapeutics.